Controls, Multiple Sclerosis, Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Conditions
Keywords
Atypical multiple sclerosis, Cavitary multiple sclerosis, Myelocortical multiple sclerosis
Brief summary
Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common. Besides multiple sclerosis, other distinct disorders including for example anti-AQP4 (aquaporine-4) and anti-MOG (Myelin oligodendrocyte glycoprotein) NMOSD (Neuromyelitis optica spectrum disorder) have been well characterized and are now known to be distinct from MS. some patient belonging to MS spectrum have recently being characterized but unusual MRI findings have mimicking inherited leukoencephalopathies and leukodystrophies. Whether these patients with atypical phenotype represent a separate disease distinct from MS or belong to MS spectrum is not clear. The objectives are to evaluate a series of 15 patients with atypical forms of MS using non-conventional MRI techniques and biological biomarkers (serum neurofilaments light chain) and to compare them with classical MS patients (15 relapsing remitting patients and 15 progressive patients) and 15 controls. the hypothesize is that these patients with atypical MS have a more severe neurodegenerative process.
Interventions
OTHERBlood withdrawal
Measurement of serum neurofilaments light chain and GFAP
OTHERMRI
Cervical and cerebral MRI without contrast injection
OTHERNeurologic / neuropsychologic tests - Patients
EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
OTHERNeurologic / neuropsychologic tests - Controls
NHPT, T25FW, CSCT
Sponsors
University Hospital, Montpellier
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* The subject must have given his informed consent and signed the consent form (if patient is protected by the law due to the study pathology, the consent will be signed his tutor or guardian ; if patient is unable to read or sign the consent form due to the study pathology, the consent will be signed by his family/trusted person) * The subject is at least 18 years old (≥). * Affiliate or beneficiary of a social security scheme Inclusion criteria specific to Patients: * Patients with atypical form of MS * OR patients with RRMS (Relapsing-Remitting Multiple Sclerosis) * OR patients with PPMS (Primary Progressive Multiple Sclerosis) (Patients will be matched on EDSS score (+/-1) and age (+/-5) ; Controls will be matched with patients on age)
Exclusion criteria
* Pregnant or lactating women. * Vulnerable people. * Simultaneous participation in any other research protocol. * Contraindication to the realization of an MRI (ferromagnetic ocular or cerebral foreign bodies close to nerve structures, pace-maker, cochlear implants) * Claustrophobic subject * Subject presenting a neurodegenerative disease (Parkinson, Alzheimer ...) * Subject presenting psychiatric disorders like psychosis, excluding anxio-depressive episode * Subject presenting a systemic pathology with neurological manifestation * Subject presenting anterior or evolutionary neurological pathology other than the 3 entities defined in the inclusion criteria * Subject presenting or having had a history of severe group 2 or 3 head trauma according to the Masters classification * Patient receiving high dose corticosteroid therapy in the 3 months prior to inclusion in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum neurofilaments light chain | Between baseline (day 0) and day 60 | Evaluation of serum neurofilaments light chain levels in patients with atypical MS and comparison with controls and patients with classical MS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum GFAP | Between baseline (day 0) and day 60 | Evaluation of serum GFAP levels in patients with atypical MS and comparison with controls and patients with classical MS |
Countries
France
Outcome results
None listed